BRPI0612424A2 - composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas - Google Patents

composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas

Info

Publication number
BRPI0612424A2
BRPI0612424A2 BRPI0612424-0A BRPI0612424A BRPI0612424A2 BR PI0612424 A2 BRPI0612424 A2 BR PI0612424A2 BR PI0612424 A BRPI0612424 A BR PI0612424A BR PI0612424 A2 BRPI0612424 A2 BR PI0612424A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
cupredoxins
signaling
ephrine
Prior art date
Application number
BRPI0612424-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Ananda Chakrabarty
Tapas Das Gupta
Tohru Yamada
Anita Chaudhari
Arsenio Fialho
Yonghua Zhu
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of BRPI0612424A2 publication Critical patent/BRPI0612424A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0612424-0A 2005-05-20 2006-05-19 composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas BRPI0612424A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68281205P 2005-05-20 2005-05-20
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US76474906P 2006-02-03 2006-02-03
PCT/US2006/019684 WO2007018671A2 (en) 2005-05-20 2006-05-19 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins

Publications (1)

Publication Number Publication Date
BRPI0612424A2 true BRPI0612424A2 (pt) 2009-01-27

Family

ID=37727776

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0612424-0A BRPI0612424A2 (pt) 2005-05-20 2006-05-19 composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas

Country Status (10)

Country Link
EP (1) EP1888106A4 (enExample)
JP (1) JP2008539795A (enExample)
KR (1) KR20080040631A (enExample)
AU (1) AU2006277009A1 (enExample)
BR (1) BRPI0612424A2 (enExample)
CA (1) CA2608512A1 (enExample)
IL (1) IL187138A0 (enExample)
MX (1) MX2007014598A (enExample)
NO (1) NO20076391L (enExample)
WO (1) WO2007018671A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
CN101437842A (zh) 2004-10-07 2009-05-20 阿南达·查克拉博蒂 铜氧还蛋白衍生的转运制剂及其应用方法
CA2615560A1 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins
JP2009502135A (ja) 2005-07-19 2009-01-29 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 血液脳関門を越えるための、および脳癌細胞内への輸送因子、並びにその使用方法
RU2009113812A (ru) * 2006-09-14 2010-10-20 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) Композиции и способы для профилактики рака с помощью купредоксинов
EP2117573A4 (en) * 2007-01-11 2011-02-16 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING EPHRIN SIGNALING WITH CUPREDOXINES AND MUTANTS THEREOF
BRPI0816094A2 (pt) 2007-08-30 2015-03-03 Daiichi Sankyo Co Ltd Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
KR101102829B1 (ko) * 2008-09-12 2012-01-05 재단법인 제주테크노파크 구멍갈파래 추출물과 그것의 항염증제로서의 용도
CN110090295B (zh) * 2018-01-29 2022-12-23 武汉康理通科技有限公司 Ephrin-B1在制备治疗炎症性肠病的药物中的用途
EP4511052A2 (en) * 2022-04-22 2025-02-26 University of Miami Ephrin ligand mimetic peptides for the treatment of neurodegenerative diseases
WO2025207820A2 (en) * 2024-03-27 2025-10-02 Mediar Therapeutics, Inc. Anti-ephrin b2 antibodies and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100955973B1 (ko) * 2001-02-15 2010-05-04 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 세포 사멸을 조절하는 세포독성인자
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death

Also Published As

Publication number Publication date
JP2008539795A (ja) 2008-11-20
IL187138A0 (en) 2008-02-09
AU2006277009A1 (en) 2007-02-15
EP1888106A4 (en) 2009-01-14
EP1888106A2 (en) 2008-02-20
CA2608512A1 (en) 2007-02-15
NO20076391L (no) 2008-02-15
KR20080040631A (ko) 2008-05-08
MX2007014598A (es) 2008-02-07
WO2007018671A2 (en) 2007-02-15
WO2007018671A3 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
EA201791850A1 (ru) Борсодержащие малые молекулы
SG170813A1 (en) New compounds
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
MX2009004047A (es) Compuestos organicos.
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
MX374896B (es) Compuestos con actividad anticáncer.
BR112012010820A2 (pt) octa-hidropirrolo[3,4-c]pirróis dissubstituídos como moduladores do receptor de orexina
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
MY151551A (en) Oxadiazole- and oxazole-substituted benzimidazole- and indole-derivatives as dgat1 inhibitors
MX2010003117A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
MX2007012237A (es) Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos.
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
NO20076391L (no) Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin
MX2010004857A (es) Compuestos de benzodiazepinona utiles en el tratamiento de afecciones de la piel.
BR112015018047A2 (pt) composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão
BR112015020667A2 (pt) método de preparar inibidores de glucosilceramida sintase
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
MX2013006366A (es) Sistema de mantenimiento para celulas reproductoras.
BRPI0607084A2 (pt) uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto
EA201000864A1 (ru) Фенилоксетанильные производные

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.